Questions: Psychopharmacology: Agonists and Antagonists

Question 1

A person overdoses on heroin (a full opioid agonist). Emergency responders administer naloxone, a pure opioid antagonist. Why does naloxone reverse the overdose?

• A. Naloxone activates opioid receptors more strongly than heroin, overriding the dangerous signal
• B. Naloxone competes for opioid receptors without activating them, displacing heroin and restoring baseline receptor activity
• C. Naloxone chemically breaks down heroin molecules in the bloodstream
• D. Naloxone activates a separate receptor that counteracts opioid signaling

Answer: (B)

Naloxone is a pure antagonist — it binds opioid receptors with high affinity but produces no activation. By outcompeting heroin for the same binding sites, it rapidly removes the agonist signal and restores normal baseline activity. It does not chemically neutralize heroin, nor does it produce any opioid effect of its own. This is the core agonist/antagonist distinction: blocking is not the same as reversing.

Question 2

An antipsychotic drug blocks dopamine D2 receptors throughout the brain. A patient reports that hallucinations have improved, but they are experiencing stiff, jerky movements. What best explains this pattern?

• A. The drug dose is too high and needs to be reduced to eliminate all side effects
• B. D2 blockade in the mesolimbic pathway reduces psychosis; D2 blockade in the nigrostriatal pathway disrupts motor control
• C. The antipsychotic is simultaneously a partial agonist in the motor cortex
• D. Dopamine blockade causes hallucinations, and the motor effects are mediated by a different neurotransmitter

Answer: (B)

The same receptor action — D2 antagonism — produces opposite-valenced effects in different circuits. Hyperactive dopamine in the mesolimbic pathway drives positive symptoms of schizophrenia; blocking D2 there reduces hallucinations. But the nigrostriatal pathway uses dopamine to coordinate smooth movement; D2 blockade there produces extrapyramidal side effects. This illustrates the core principle: predicting behavioral effects requires knowing which circuits the receptor change is embedded in, not just the receptor action itself.

Question 3

A partial agonist can act as a functional antagonist when competing against a full agonist at the same receptor.

• T. True
• F. False

Answer: True

When a partial agonist occupies receptor sites that would otherwise be activated by a full agonist, the net effect is reduced signaling — the partial agonist displaces the full agonist and produces less activation. This is why buprenorphine (a partial opioid agonist) can precipitate withdrawal in patients currently on full opioid agonists: it displaces the full agonist but provides less total receptor activation. Context determines whether a partial agonist looks like an agonist (vs. baseline) or an antagonist (vs. a full agonist).

Question 4

An antagonist produces the opposite effect of the natural neurotransmitter at that receptor.

• T. True
• F. False

Answer: False

An antagonist occupies the receptor without activating it — it produces NO direct signaling effect, not the opposite effect. The consequence is that the natural neurotransmitter cannot bind, so its effect is prevented. Any 'opposite-seeming' outcome (e.g., blocking an inhibitory receptor causes excitability) is an indirect circuit-level consequence, not the direct receptor action. Antagonists are blockers, not reversers — this distinction matters for predicting drug effects accurately.

Question 5

Why can a partial agonist have both agonist-like and antagonist-like effects depending on what else is present in the system?

Model answer: A partial agonist activates the receptor to some submaximal degree regardless of what it is competing against. When no other agonist is present, it provides net activation (agonist-like). When a full agonist is present, it competes for the same binding sites and produces less total receptor activation than the full agonist would alone — a net reduction (antagonist-like). The effect depends on what it is competing against, not on any change in the partial agonist itself.

This is the clinical logic behind buprenorphine: in a patient with no opioids on board, it provides pain relief and suppresses withdrawal (agonist effect). In a patient actively using heroin, it displaces heroin and reduces total opioid signaling (antagonist-like effect). The receptor doesn't 'choose' — the outcome is determined by which molecules are competing for the binding site and how much activation each produces. Understanding this dual nature is essential for predicting and managing therapeutic windows in pharmacology.